OpenEvidence is a leading AI driven clinical decision support tool.
getty
OpenEvidence’s CEO, Daniel Nadler, confirmed this week that it has raised an additional $250 million, reaching a $15 billion dollar valuation. This is huge news for the clinical intelligence company, which has largely taken the industry by storm and has been viewed as a positive addition to clinical workflows by physicians across the board.
The company has gained significant market share over the last two years. Additionally, famed frontier model company Anthropic and OpenEvidence recently announced that the companies will be partnering to increase physician access to AI enabled decision intelligence, especially across Africa and Asia. An exclusive report by Reuters indicated that OpenEvidence will use Anthropic’s base models to fine-tune its tool for respective countries, and is planning to roll it out across nearly 100 countries for free. The tool is currently free for physicians in the United States, and is often touted as one of the best clinical decision making systems in the industry.
The goal is to help significantly increase access across the globe to more robust artificial intelligence tools in clinical practice, and thereby also increase AI literacy worldwide. Furthermore, leveraging Anthropic’s top tier models will help better customize medical recommendations to local guidelines and needs, with the hope of augmenting physician workflows in real-time.
OpenEvidence is certainly not the only player in this field. Numerous other new and legacy companies have entered the clinical decision intelligence and support market to try and gain a portion of market share. For example, legacy player UpToDate, which for decades has been the leader in physician access to clinical information and support, has its own AI enabled tool for clinicians to use in care delivery settings. Another prominent example is Doximity, which also has its own tool and boasts nearly 3+ million healthcare users on its ecosystem. Though the competition is fierce, the goal is similar: enabling physicians to have the best toolsets available at the point of care to be able to enable efficient clinical decision making.
Interestingly, the frontier AI companies have been recently criticized for partnering with companies whose businesses they are trying to emulate themselves. Realistically, Anthropic and the rest of the labs are attempting to become increasingly relevant and frontline in the clinical intelligence space.
Thus, by no means is the future of healthcare AI already certain, especially with regard to the clinical intelligence market specifically. Although valuations are rapidly continuing to increase, time will tell who is able to best provide tailored service to users.
Leave a comment